Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating...

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Deregulation of phosphoinositide-3-kinase (PI3K) signaling is implicated in numerous human cancers, making PI3Ks critical oncology targets.
• Targeting the PI3K pathway offers a promising therapeutic strategy for various malignancies.

Purpose of the Study:

• To optimize 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines as potent PI3K inhibitors.
• To improve pharmacokinetic and druglike properties through structure-guided modifications.
• To identify novel PI3K inhibitors with potential for cancer treatment.

Main Methods:

• Structure-guided optimization of pyrimidine derivatives.
• Modulation of electronic properties at the 6-position heterocycle to enhance pharmacokinetics.
• Fine-tuning of 4-position substituents to optimize druglike characteristics.
• In vitro assays for PI3K inhibition and mechanism modulation in cancer cell lines.
• In vivo efficacy studies in tumor xenograft models.

Main Results:

• Discovery of 2,4-bismorpholino 6-heterocyclic pyrimidines as potent class I PI3K inhibitors.
• Demonstrated mechanism modulation in PI3K-dependent cancer cell lines.
• Exhibited in vivo efficacy in A2780 ovarian and U87MG glioma tumor xenograft models.
• Identification of compound 15 (NVP-BKM120) as a lead candidate.

Conclusions:

• The optimized pyrimidine series effectively inhibits PI3K signaling.
• NVP-BKM120 shows significant preclinical efficacy in relevant cancer models.
• NVP-BKM120 represents a promising therapeutic candidate for cancers with PI3K pathway deregulation and is currently undergoing Phase II clinical trials.